Accelerate Diagnostics

Accelerate Diagnostics Days Inventory Outstanding

Delisted

The Days Inventory Outstanding (DIO) of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 115.74. In the previous year, Days Inventory Outstanding (DIO) was 127.05 — a change of -8.90% (lower).

Days Inventory Outstanding

115.74

YoY

-8.90%

Last updated:

Days Inventory Outstanding (DIO) of Accelerate Diagnostics is 2024 115.74 . Days Inventory Outstanding (DIO) of Accelerate Diagnostics was 2023 127.05 . It decreases by -8.90% lower compared to the previous year.

The Accelerate Diagnostics Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2017
2,937.12 USD
Jan 1, 2018
887.13 USD
Jan 1, 2019
600.68 USD
Jan 1, 2020
501.62 USD
Jan 1, 2021
152.06 USD
Jan 1, 2022
200.64 USD
Jan 1, 2023
127.05 USD
Jan 1, 2024
115.74 USD
The Accelerate Diagnostics Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
115.74-8.90%
127.05-36.67%
200.64+31.95%
152.06-69.69%
501.62-16.49%
600.68-32.29%
887.13-69.80%
2,937.12+110,624.05%
2.65-80.52%
13.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Days Inventory Outstanding (DIO) of Accelerate Diagnostics is 115.74 in 2024.

Days Inventory Outstanding (DIO) of Accelerate Diagnostics changed from 127.05 to 115.74, representing a -8.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Accelerate Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics